Aging-resistant organophosphate bioscavenger based on polyethylene glycol-conjugated F338A human acetylcholinesterase

Molecular Pharmacology

Volumn 74, Issue 3, 2008, Pages 755-763

  Mazor, Ohad ^a   Cohen, Ofer ^a   Kronman, Chanoch ^a   Raveh, Lily ^a   Stein, Dana ^a   Ordentlich, Arie ^a   Shafferman, Avigdor ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; 7 [(ETHOXY)(METHYL)PHOSPHINOYLOXY] 1 METHYLQUINOLINIUM IODIDE; ACETYLCHOLINESTERASE; BIOSCAVENGER; CHOLINESTERASE REACTIVATOR; CRESYLBENZODIOXAPHOSPHORIN OXIDE; MACROGOL; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; NERVE GAS; ORGANOPHOSPHATE; OXIME; POLYETHYLENE GLYCOL CONJUGATED F338A ACETYLCHOLINESTERASE; RECOMBINANT ENZYME; SARIN; SCAVENGER; SOMAN; UNCLASSIFIED DRUG;

AGING; ANIMAL EXPERIMENT; ARTICLE; CONJUGATION; DEALKYLATION; EMBRYO; ENZYME INACTIVATION; ENZYME REACTIVATION; HUMAN; HUMAN CELL; HYDROLYSIS; INTOXICATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; ALANINE; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; CELL LINE; CHOLINESTERASE INHIBITORS; ENZYME ACTIVATION; HUMANS; HYDROLYSIS; KINETICS; MALE; MICE; MICE, INBRED ICR; ORGANOPHOSPHORUS COMPOUNDS; PHENYLALANINE; PHOSPHORYLATION; POLYETHYLENE GLYCOLS; SOMAN; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 50449109993     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.047449     Document Type: Article

References (39)

1. Ariel N, Ordentlich A, Barak D, Bino T, Velan B, and Shafferman A (1998) The "aromatic patch" of three proximal residues in the human acetylcholinesterase active center allows for versatile interaction modes with inhibitors. Biochem J 335:95-102.
2. Ashani Y, Grauer E, Grunwald J, Allon N, and Raveh L (1998) Current capabilities in extrapolating from animal to human the capacity of human butyrylcholinesterase to detoxify organophosphates, in Structure and Function of Cholinesterases and Related Proteins (Doctor BP, Quinn DM, Rotundo RL, and Taylor P eds), pp 255-260, Plenum Press, New York.
3. Barak D, Kronman C, Ordentlich A, Ariel N, Bromberg A, Marcus D, Lazar A, Velan B, and Shafferman A (1994) Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J Biol Chem 269:6296-6305.
4. Barak D, Ordentlich A, Segall Y, Velan B, Benschop HP, de Jong LP, and Shafferman A (1997) Carbocation-mediated processes in biocatalysts. Contribution of aromatic moieties. J Am Chem Soc 13:3157-3158.
5. Chilukuri N, Parikh K, Sun W, Naik R, Tipparaju P, Doctor BP, and Saxena A (2005) Polyethylene glycosylation prolongs the circulatory stability of recombinant human butyrylcholinesterase. Chem Biol Interact 157-158:115-121.
6. Chitlaru T, Kronman C, Velan B, and Shafferman A (2001) Effect of human acetylcholinesterase subunit assembly on its circulatory residence. Biochem J 354:613-625.
7. Cohen O, Kronman C, Chitlaru T, Ordentlich A, Velan B, and Shafferman A (2001) Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity. Biochem J 357:795-802.
8. Cohen O, Kronman C, Velan B, and Shafferman A (2004) Amino acid domains control the circulatory residence time of primate acetylcholinesterases in rhesus macaques. Biochem J 378:117-128.
9. Cohen O, Kronman C, Raveh L, Mazor O, Ordentlich A, and Shafferman A (2006) Comparison of polyethylene glycol-conjugated recombinant human acetylcholinesterase and serum human butyrylcholinesterase as bioscavengers of organophosphate compounds. Mol Pharmacol 70:1121-1131.
10. Cohen O, Kronman C, Lazar A, Velan B, and Shafferman A (2007) Controlled concealment of exposed clearance and immunogenic domains by site-specific polyethylene glycol attachment to acetylcholinesterase hypolysine mutants. J Biol Chem 282:35491-35501.
11. Dawson RM (1994) Review of oximes available for treatment of nerve agents poisoning. J Appl Toxicol 14:317-331.
12. de Jong LP and Kossen SP (1985) Stereospecific reactivation of human brain and erythrocyte acetylcholinesterase inhibited by 1,2,2-trimethylpropyl methylphosphonofluoridate (soman). Biochim Biophys Acta 830:345-348.
13. de Jong LP, van Dijk C, and Benschop HP (1988) Hydrolysis of the four stereoisomers of soman catalyzed by liver homogenate and plasma from rat, guinea pig and marmoset and by human plasma. Biochem Pharmacol 37:2939-2948.
14. Ellman GL, Courtney KD, Andres V Jr, and Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
15. Fischer M, Ittah A, Liefer I, and Gorecki M (1993) Expression and reconstitution of biologically active human acetylcholinesterase from E. Coli. Cell Mol Neurobiol 13:25-38.
16. Fleisher JH and Harris LW (1965) Dealkylation as a mechanism for aging of cholinesterase after poisoning with pinacolyl methylphosphonofluoridate. Biochem Pharmacol 14:641-650.
17. Grosfeld H, Barak D, Ordentlich A, Velan B, and Shafferman A (1996) Interaction of oxime reactivators with diethylphosphoryl adducts of human acetylcholinesterase and its mutant derivatives. Mol Pharmacol 50:639-649.
18. Harris JM and Chess RB (2003) Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
19. Kronman C, Velan B, Gozes Y, Leitner M, Flashner Y, Lazar A, Marcus D, Sery T, Papier Y, and Grosfeld H (1992) Production and secretion of high levels of recombinant human acetylcholinesterase in cultured cell lines: microheterogeneity of the catalytic subunit. Gene 121:295-304.
20. Kronman C, Velan B, Marcus D, Ordentlich A, Reuveny S, and Shafferman A (1995) Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from circulation. Biochem J 311:959-967.
21. Kronman C, Cohen O, Raveh L, Mazor O, Ordentlich A, and Shafferman A (2007) Polyethylene-glycol conjugated recombinant human acetylcholinesterase serves as an efficacious bioscavenger against soman intoxication. Toxicology 233:40-46.
22. Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA, and Cerasoli DM (2007) Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology 233:31-39.
23. Levy D and Ashani Y (1986) Synthesis and in vitro properties of a powerful quaternary methylphosphonate inhibitor of acetylcholinesterase. A new marker in bloodbrain barrier research. Biochem Pharmacol 35:1079-1085.
24. Masson P, Adkins S, Gouet P, and Lockridge O (1993) Recombinant human butyrylcholinesterase G390V, the fluoride-2 variant, expressed in Chinese hamster ovary cells, is a low affinity variant. J Biol Chem 268:14329-14341.
25. Masson P, Fortier PL, Albaret C, Froment MT, Bartels CF, and Lockridge O (1997) Aging of di-isopropyl-phosphorylated human butyrylcholinesterase. Biochem J 327:601-607.
26. Maxwell DM, Brecht KM, Doctor BP, and Wolfe AD (1993) Comparison of antidote protection against soman by pyridostigmine, HI-6 and acetylcholinesterase. J Pharmacol Exp Ther 264:1085-1089.
27. Millard CB, Koellner G, Ordentlich A, Shafferman A, Silman I, and Sussman JL (1999) Reaction products of acetylcholinesterase and VX reveal a mobile histidine in the catalytic triad. J Am Chem Soc 121:9883-9884.
28. Ordentlich A, Kronman C, Barak D, Stein D, Ariel N, Marcus D, Velan B, and Shafferman A (1993) Engineering resistance to "aging" of phosphylated human acetylcholinesterase. Role of hydrogen bond network in the active center. FEBS Lett 334:215-220.
29. Ordentlich A, Barak D, Kronman C, Ariel N, Segall Y, Velan B, and Shafferman A (1996) The architecture of human acetylcholinesterase active center probed by interactions with selected organophosphate inhibitors. J Biol Chem 271:11953-11962.
30. Ordentlich A, Barak D, Kronman C, Ariel N, Segall Y, Velan B, and Shafferman A (1998) Functional characteristics of the oxyanion hole in human acetylcholinesterase. J Biol Chem 273:19509-19517.
31. Ordentlich A, Barak D, Kronman C, Benschop HP, De Jong LP, Ariel N, Barak R, Segall Y, Velan B, and Shafferman A (1999) Exploring the active center of human acetylcholinesterase with stereomers of an organophosphorous inhibitor with two chiral centers. Biochemistry 38:3055-3066.
32. Ordentlich A, Barak D, Sod-Moriah G, Kaplan D, Mizrahi D, Segall Y, Kronman C, Karton Y, Lazar A, Marcus D, et al. (2005) The role of AChE active site gorge in determining stereoselectivity of charged and noncharged VX enantiomers. Chem Biol Interact 157-158:191-198.
33. Radić Z, Pickering NA, Vellom DC, Camp S, and Taylor P (1993) Three distinct domains in the cholinesterase active center allows for versatile interaction modes with inhibitors. Biochemistry 32:12074-12084.
34. Raveh L, Grunwald J, Marcus D, Papier Y, Cohen E, and Ashani Y (1993) Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol 45:2465-2474.
35. Raveh L, Grauer E, Grunwald J, Cohen E, and Ashani Y (1997) The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol Appl Pharmacol 145:43-53.
36. Shafferman A, Ordentlich A, Barak D, Stein D, Ariel N, and Velan B (1996) Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active center. Biochem J 318:833-840.
37. Shafferman A, Barak D, Kaplan D, Ordentlich A, Kronman C, and Velan B (2005) Functional requirements for the optimal catalytic configuration of the AChE active center. Chem Biol Interact 157-158:123-131.
38. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, and Silman I (1991) Atomic structure of acetylcholinesterase from Torpedo california: a prototypic acetylcholine-binding protein. Science 253:872-879.
39. Worek F, Thiermann H, Szinicz L, and Eyer P (2004) Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem Pharmacol 68:2237-2248.